On March 6, 2019
Harry Karelis wants to turn ex-tech wreck 1 Page into a pot stock worth as much as all the ASX pot stocks combinedHarry Karelis’ next cannabis gig is at former tech-wreck 1 Page — now delisted in Australia and soon to be known as European Cannabis Corporation.
Mr Karelis stepped back from a hands-on role at biotech
Zelda (ASX:ZLD) in January, where he remains chair, and is now chairing the German-focused company. He also helped launch
AusCann (ASX:AC8).
He and partner-in-cannabis Andrew Chapman from Perth financier Merchant Group plan to list European Cannabis on the AIM in London between September and November this year.
“Chappie and I started our cannabis adventure together about five years ago which makes us grand-daddies of the industry, globally,” he told
*.
“I’m pretty active in starting up companies and getting them to a certain level and stepping back.”
He didn’t want to publicly reveal the market cap they’re aiming for, but says by the time they list, the new company should be delivering the same level of revenue as all of the ASX pot stocks combined, and have an equivalent market cap.
*’s list of 31 pot stocks and cannabis wannabes have a combined market cap of about $1.6 billion. The 17 doing purely or mostly cannabis have a combined market cap of about $1.5 billion.
From dot com bomb to pot stock1 Page signed on to
buy German cannabis drug maker HAPA Medical Group in February last year, as way to use the $23 million it had in the bank and reform from the tech disaster it had become.
Led by founder Joanna Riley, Silicon Valley based 1 Page surged 70 per cent on its ASX debut in 2014 — and then rapidly rose more than 2500 per cent to $5.69 in September 2016, amid intense speculation.
By March 2017, however, the stock had dropped all the way back to 15.5c as Mrs Riley tried — and failed — to roll the board. It was described by the board at the time as
“her intention to continue to burn cash”.
Ms Riley ceased as a substantial shareholder in August when she sold $2.6 million in shares. In December, she stepped down as CEO “to focus on strategy and business development”.
The company was delisted in July last year, promising existing investors
a big payoff for their patience, but in another country. At the time Mr Chapman was considering Frankfurt or Canada for a listing.
Mr Chapman told
* last week they chose the AIM because of the UK’s recent move to legalise medical cannabis, the novelty of cannabis in that market compared to Canada, and because of its proximity to their new operations.
Selling drugs in GermanyMr Karelis says HAPA is now a multi-million euro revenue business and will be cash flow positive this year. When they bought in last year, it was still a startup.
